{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:59:53Z","timestamp":1789070393686,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08119-5","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:44:58Z","timestamp":1777185898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6828-5354","authenticated-orcid":false,"given":"Sergi","family":"L\u00f3pez-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinto","family":"Segal\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Urretavizcaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bertol\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Mench\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa","family":"del Pino Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"issue":"1","key":"8119_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-019-0102-3","volume":"5","author":"DJ Stein","year":"2019","unstructured":"Stein DJ, Craske MA, Rothbaum BO, et al. Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019;5(1):52.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"8119_CR2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1176\/appi.ajp.2008.08020320","volume":"165","author":"MH Bloch","year":"2008","unstructured":"Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF. Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry. 2008;165(12):1532\u201342.","journal-title":"Am J Psychiatry"},{"issue":"Suppl 4","key":"8119_CR3","first-page":"2","volume":"58","author":"The Expert Consensus Panel for Obsessive-Compulsive Disorder","year":"1997","unstructured":"The Expert Consensus Panel for Obsessive-Compulsive Disorder. Treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(Suppl 4):2\u201372.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"8119_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","volume":"30","author":"S Pallanti","year":"2006","unstructured":"Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):400\u201312.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"8119_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"AM Ruscio","year":"2010","unstructured":"Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53\u201363.","journal-title":"Mol Psychiatry"},{"key":"8119_CR6","doi-asserted-by":"publisher","first-page":"703701","DOI":"10.3389\/fpsyt.2021.703701","volume":"12","author":"E Sharma","year":"2021","unstructured":"Sharma E, Sharma LP, Balachander S, Lin B, Manohar H, Khanna P, et al. Comorbidities in Obsessive-Compulsive Disorder Across the Lifespan: A Systematic Review and Meta-Analysis. Front Psychiatry. 2021;12:703701. https:\/\/doi.org\/10.3389\/fpsyt.2021.703701.","journal-title":"Front Psychiatry"},{"key":"8119_CR7","doi-asserted-by":"publisher","unstructured":"Quarantini LC, Torres AR, Sampaio AS, Fossaluza V, de Mathis MA, do Ros\u00e1rio MC, et al. Comorbid major depression in obsessive-compulsive disorder patients. Compr Psychiatry. 2011;52(4):386\u201393. https:\/\/doi.org\/10.1016\/j.comppsych.2010.09.006.","DOI":"10.1016\/j.comppsych.2010.09.006"},{"issue":"5","key":"8119_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-021-00816-x","volume":"35","author":"ID Henter","year":"2021","unstructured":"Henter ID, Park LT, Zarate CA Jr. Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs. 2021;35(5):527\u201343. https:\/\/doi.org\/10.1007\/s40263-021-00816-x.","journal-title":"CNS Drugs"},{"issue":"3","key":"8119_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","volume":"132","author":"C Pittenger","year":"2011","unstructured":"Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011;132(3):314\u201332. https:\/\/doi.org\/10.1016\/j.pharmthera.2011.09.006.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"8119_CR10","doi-asserted-by":"publisher","first-page":"e2452963","DOI":"10.1001\/jamanetworkopen.2024.52963","volume":"8","author":"DRA Coelho","year":"2025","unstructured":"Coelho DRA, Yang C, Suriaga A, et al. Glutamatergic Medications for Obsessive-Compulsive and Related Disorders: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2025;8(1):e2452963. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.52963.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"8119_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/HRP.0000000000000322","volume":"30","author":"ID Bandeira","year":"2022","unstructured":"Bandeira ID, Lins-Silva DH, Cavenaghi VB, et al. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harv Rev Psychiatry. 2022;30(2):135\u201345. https:\/\/doi.org\/10.1097\/HRP.0000000000000322.","journal-title":"Harv Rev Psychiatry"},{"issue":"4","key":"8119_CR12","doi-asserted-by":"publisher","first-page":"e37833","DOI":"10.7759\/cureus.37833","volume":"15","author":"AA Ferguson","year":"2023","unstructured":"Ferguson AA, Khan AI, Abuzainah B, et al. Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review. Cureus. 2023;15(4):e37833. https:\/\/doi.org\/10.7759\/cureus.37833.","journal-title":"Cureus"},{"issue":"7","key":"8119_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/brainsci11070856","volume":"11","author":"G Martinotti","year":"2021","unstructured":"Martinotti G, Chiappini S, Pettorruso M, et al. Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. Brain Sci. 2021;11(7):856. https:\/\/doi.org\/10.3390\/brainsci11070856.","journal-title":"Brain Sci"},{"issue":"8","key":"8119_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00406-019-01056-3","volume":"270","author":"M Gim\u00e9nez","year":"2020","unstructured":"Gim\u00e9nez M, Cano M, Mart\u00ednez-Zalaca\u00edn I, et al. Is glutamate associated with fear extinction and cognitive behavior therapy outcome in OCD? A pilot study. Eur Arch Psychiatry Clin Neurosci. 2020;270(8):1003\u201314. https:\/\/doi.org\/10.1007\/s00406-019-01056-3.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"12","key":"8119_CR15","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1038\/npp.2017.77","volume":"42","author":"J O\u2019Neill","year":"2017","unstructured":"O\u2019Neill J, Piacentini J, Chang S, et al. Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial. Neuropsychopharmacology. 2017;42(12):2414\u201322. https:\/\/doi.org\/10.1038\/npp.2017.77.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"8119_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","volume":"74","author":"D Mataix-Cols","year":"2017","unstructured":"Mataix-Cols D, Fern\u00e1ndez de la Cruz L, Monzani B, et al. d-Cycloserine augmentation of exposure-based CBT for anxiety, obsessive-compulsive, and posttraumatic stress disorders: A systematic review and meta-analysis of individual participant data. JAMA Psychiatry. 2017;74(5):501\u201310.","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"8119_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):139\u201348.","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"8119_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021;178(5):383\u201399. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081251.","journal-title":"Am J Psychiatry"},{"key":"8119_CR19","doi-asserted-by":"publisher","unstructured":"Sanacora G, Nikayin S, Charney DS, Murrough JW. Ketamine and esketamine for treatment-resistant depression. Therapies for treatment-resistant depression: neuropharmacology and neurostimulation. Elsevier; 2025;103\u201321. https:\/\/doi.org\/10.1016\/B978-0-443-16005-9.00003-9.","DOI":"10.1016\/B978-0-443-16005-9.00003-9"},{"key":"8119_CR20","doi-asserted-by":"publisher","first-page":"120231","DOI":"10.1016\/j.jad.2025.120231","volume":"392","author":"M Olivola","year":"2026","unstructured":"Olivola M, Mazzoni F, Tarantino B, Guffanti A, Marcatili M, Motta FL, et al. Mentalization and Emotional-Cognitive Rigidity as predictors of esketamine\u2019s effects on Treatment-Resistant Depression: Findings from a prospective observational study. J Affect Disord. 2026;392:120231. https:\/\/doi.org\/10.1016\/j.jad.2025.120231.","journal-title":"J Affect Disord"},{"issue":"5","key":"8119_CR21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2174\/011570159X337670241029062524","volume":"23","author":"G Rosso","year":"2025","unstructured":"Rosso G, d\u2019Andrea G, Barlati S, Di Nicola M, Andriola I, Marcatili M, et al. Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group. Curr Neuropharmacol. 2025;23(5):612\u20139. https:\/\/doi.org\/10.2174\/011570159X337670241029062524.","journal-title":"Curr Neuropharmacol"},{"issue":"6","key":"8119_CR22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1159\/000539714","volume":"57","author":"P Sarasso","year":"2024","unstructured":"Sarasso P, Billeci M, Ronga I, Raffone F, Martiadis V, Di Petta G. Disembodiment and Affective Resonances in Esketamine Treatment of Depersonalized Depression Subtype: Two Case Studies. Psychopathology. 2024;57(6):480\u201391. https:\/\/doi.org\/10.1159\/000539714.","journal-title":"Psychopathology"},{"issue":"1","key":"8119_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/WNF.0000000000000578","volume":"47","author":"R Alves-Pereira","year":"2024","unstructured":"Alves-Pereira R, Fontes M, Cordeiro V, Bandeira ID, Faria-Guimar\u00e3es D, Silva SS, et al. Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Retrospective Chart Review. Clin Neuropharmacol. 2024;47(1):17\u201321. https:\/\/doi.org\/10.1097\/WNF.0000000000000578.","journal-title":"Clin Neuropharmacol"},{"key":"8119_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, \u00c5sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"issue":"11","key":"8119_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006\u201311.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"8119_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. II Validity Arch Gen Psychiatry. 1989;46(11):1012\u20136.","journal-title":"II Validity Arch Gen Psychiatry"},{"issue":"2","key":"8119_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4088\/JCP.v67n0214","volume":"67","author":"HB Simpson","year":"2006","unstructured":"Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(2):269\u201376.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"8119_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4088\/JCP.12m07789","volume":"74","author":"SG Farris","year":"2013","unstructured":"Farris SG, McLean CP, Van Meter PE, Simpson HB, Foa EB. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. J Clin Psychiatry. 2013;74(7):685\u201390. https:\/\/doi.org\/10.4088\/JCP.12m07789.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"8119_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12991-021-00365-z","volume":"20","author":"M Marcatili","year":"2021","unstructured":"Marcatili M, Pellicioli C, Maggioni L, Motta F, Redaelli C, Ghelfi L, et al. The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report. Ann Gen Psychiatry. 2021;20(1):43. https:\/\/doi.org\/10.1186\/s12991-021-00365-z.","journal-title":"Ann Gen Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08119-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08119-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08119-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:45:37Z","timestamp":1781649937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08119-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8119"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08119-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7417012\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Bellvitge University Hospital Clinical Research Ethics Committee (Acta 25\/24; CEIm entry 2024\/2492). All participants provided written informed consent prior to inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"469"}}